Emergence of advanced immunotherapy: New horizons for HPV-negative head and neck squamous cell carcinoma

Head and neck squamous cell carcinoma (HNSCC) is a complex group of malignancies that exhibit distinct clinical and molecular characteristics, especially in the HPV-negative subset. The treatment landscape for HPV-negative HNSCC has historically been limited to surgery, radiation, and chemotherapy, with these modalities often yielding suboptimal outcomes. The emergence of advanced immunotherapy represents a paradigm shift, offering new therapeutic options for this challenging cancer type. This review provides a comprehensive analysis of the latest advancements in immunotherapy for HPV-negative HNSCC, focusing on, chimeric antigen receptor (CAR) T-cell therapy, therapeutic cancer vaccines and immune checkpoint inhibitors. It also explores the potential benefits and limitations of combining immunotherapy with other treatment modalities including chemotherapy, targeted therapy, and radiation. Key challenges, including tumor heterogeneity, immunosuppressive microenvironment, and resistance mechanisms, are discussed. The review concludes with a look at future research directions and strategies to overcome these challenges and improve patient outcomes. • CAR T-Cell Therapy Potential: The title hints at the promise of CAR T-cell therapy, which involves engineering patients' T-cells to target tumor-specific antigens, offering a personalized and targeted approach for HPV-negative head and neck squamous cell carcinoma. • Therapeutic Vaccines Development: The emerging use of therapeutic cancer vaccines, designed to stimulate the immune system to recognize and attack tumor cells, represents a growing area of research for addressing HPV-negative HNSCC. • Immune Checkpoint Inhibition: Immune checkpoint inhibitors, such as anti-PD-1/PD-L1 therapies, are highlighted as key players in enhancing the immune system’s ability to detect and destroy cancer cells in HPV-negative HNSCC. • Addressing Resistance Mechanisms: The mention of "New Horizons" implies ongoing efforts to overcome resistance to immunotherapy, a significant hurdle in treating HPV-negative head and neck cancers, particularly in patients with immunosuppressive tumor microenvironments.